



governmentattic.org

"Rummaging in the government's attic"

Description of document: Dr. Bruce Ivins emails provided by
TheEnterpriseReport.com
Email Batch Four

Released date: 2009

Posted date: 17-November-2009

Date/date range of documents: 14-June-1999 – 04-May-2000

Source of document: US Army Medical Research and Materiel Command
Fort Detrick, MD

Note: See following page for other related material available from
governmentattic.org

The governmentattic.org web site ("the site") is noncommercial and free to the public. The site and materials made available on the site, such as this file, are for reference only. The governmentattic.org web site and its principals have made every effort to make this information as complete and as accurate as possible, however, there may be mistakes and omissions, both typographical and in content. The governmentattic.org web site and its principals shall have neither liability nor responsibility to any person or entity with respect to any loss or damage caused, or alleged to have been caused, directly or indirectly, by the information provided on the governmentattic.org web site or in this file. The public records published on the site were obtained from government agencies using proper legal channels. Each document is identified as to the source. Any concerns about the contents of the site should be directed to the agency originating the document in question. GovernmentAttic.org is not responsible for the contents of documents published on the website.

THE ENTERPRISE REPORT - TheEnterpriseReport.com

is an online investigative news site founded and published by award-winning Producer/Investigative Journalist Eric Longabardi. The site was named Best Online Website by the LA Press Club in 2008.

Eric Longabardi is a national award winning broadcast producer and investigative journalist with a career spanning nearly two decades. Longabardi has reported extensively on a wide variety issues related to the US Defense Department's research into biological and chemical weapons over the years. He has also reported extensively on the FBI 'Amerithrax' investigation of Dr. Bruce Ivins, the Fort Detrick, Maryland biowarfare scientist the U.S. Department of Justice (DOJ) claims was the person responsible for mailing Anthrax letters which killed five people and sickened 17 others in 2001. Longabardi was the first journalist to disclose the movements and detail the "window of opportunity" of Dr. Ivins on the dates the Anthrax letters were mailed and detail his whereabouts at the Fort Detrick Laboratory where he worked during the dates in question.

The nine batches of emails provided to governmentattic.org were obtained under the Freedom of Information Act (FOIA) by journalist Eric Longabardi beginning on January 22, 2009.

All of this material is available at governmentattic.org.

This file is: Email Batch Four: [DrBruceIvinsEmail_Four.pdf](#) 224 KB

The other available files are:

The Release letter:	DrBruceIvinsEmail_ReleaseLetter.pdf	30 KB
Email Batch One:	DrBruceIvinsEmail_One.pdf	7 MB
Email Batch Two:	DrBruceIvinsEmail_Two.pdf	170 KB
Email Batch Three:	DrBruceIvinsEmail_Three.pdf	264 KB
Email Batch Five:	DrBruceIvinsEmail_Five.pdf	124 KB
Email Batch Six:	DrBruceIvinsEmail_Six.pdf	130 KB
Email Batch Seven:	DrBruceIvinsEmail_Seven.pdf	145 KB
Email Batch Eight:	DrBruceIvinsEmail_Eight.pdf	221 KB
Email Batch Nine:	DrBruceIvinsEmail_Nine.pdf	329 KB
All above material in one PDF:	DrBruceIvinsEmail_All.pdf	6.2 MB

From: Ivins, Bruce E Dr USAMRIID

Sent: Tuesday, March 07, 2000 3:24 PM

To: (b) (6) SAMRIID; (b) (6) USAMRIID

Subject: (b) (6)

Hi, (b) (6)

Here are the email address and telephone for (b) (6) t the
American Society For Microbiology.

(b) (6)

(b) (6)

- Bruce

From: Ivins, Bruce E Dr USAMRIID
Sent: Tuesday, March 07, 2000 8:59 AM
To: (b) (6)
Subject: RE: Policy question

Hi, (b) (6) would be the person to contact. He is the safety person here.
301 (b) (6) s his phone number here. My best to (b) (6) (b) (6)

- Bruce

-----Original Message-----

From: (b) (6)
Sent: Monday, March 06, 2000 5:22 PM
To: 'Ivins, Bruce E Dr USAMRIID'
Subject: RE: Policy question

Thank you, Bruce. Who would be the official person to respond to my question?

(b) (6)

(b) (6)

who is the person in USAMRIID to direct the query to officially?

Have a good evening.

(b) (6)

> -----Original Message-----

> From: Ivins, Bruce E Dr USAMRIID [SMTP:Bruce.Ivins@usamriid.gov] (b) (6)
> Sent: Monday, March 06, 2000 11:11 AM
> To: (b) (6)
> Subject: RE: Policy question

> Hi (b) (6) So nice to hear from you, (b) (6) here at

> USAMRIID, pregnant women are not allowed in biocontainment suites, at least the BL-3 suites where they work with B. anthracis. Talk to you later!

> - Bruce

> -----Original Message-----

> From: (b) (6)

> Sent: Monday, March 06, 2000 8:53 AM
> To: 'Bruce.Ivins@DET.AMEDD.ARMY.MIL'
> Subject: Policy question

>
>
> Dear Bruce,

> Hi! I think you know I am doing this spell at (b) (6)
> them to retrieve lost low-tech anthrax skills.I believe (b) (6)
> conveyed my good wishes (b) (6) in DC.

>
> Can you tell me whether there is a policy in place in USAMRIID
> regarding pregnant women working with B. anthracis? This is assuming
> that, at the time they learn they are pregnant, their vaccination status is
OK.

>
> (b) (6)
> [Redacted text block]

>
> Enough flattery, I must get back to work!

>
> Usual best wishes,

> (b) (6)

From: Ivins, Bruce E Dr USAMRIID
Sent: Tuesday, March 07, 2000 9:13 AM
To: (b) (6) USAMRIID
Subject: RE: Rabbit Bleed

Dearest Colleague,

Have you checked with the STO manager as to the acceptability of this change in procedure? If not, I suggest that you immediately schedule an appointment and prepare to perform numerous experiments to demonstrate that the change in bleeding dates will have no effect on the response to the anthrax vaccine, the response to challenge, or the response of natives in Borneo to increased rainfall.

- Your buddy,
Bruce - hey! big man! hey! Is (b) (6) back there?

>-----Original Message-----

>From: (b) (6) USAMRIID
>Sent: Tuesday, March 07, 2000 7:24 AM
>To: (b) (6) USAMRIID; Ivins, Bruce E Dr USAMRIID
>Cc: (b) (6) USAMRIID
>Subject: Rabbit Bleed

>

> (b) (6)

> I was looking at the schedule for B00-03 and noticed that you have bleeds scheduled for the same day as challenges. I suggest that you move these bleed to 30 and 31 March. The rabbits are put in the plethysmograph prior to challenge so that the inhaled spore dose can be calculated. The rabbits need to be awake for this procedure. Bruce, (b) (6) and I can help with the bleeds those days if necessary.

>

(b) (6)

From: Ivins, Bruce E Dr USAMRIID
Sent: Wednesday, March 08, 2000 7:21 AM
To: (b) (6) USAMRIID
Subject: FW: URL for conference form

Importance: High

Hi, (b) (6)

I got a call from (b) (6) late yesterday afternoon. (b) (6) said that the ASM is not really asking for an amount of money. The ASM is looking for a contractual guarantee that the Army will "share the risk" for the meeting. She again stated that they are not asking for a grant of money.

If the Army insists that the BAA application form be filled out, (b) (6) said that (b) (6) will need some help from us filling out certain parts of it, since some of the information being requested (b) (6) doesn't know.

Finally, (b) (6) emphasized the need for quick action, since the hotel where we want to hold certain functions needs to get a commitment in writing, or they can't reserve it for us.

Please call (b) (6) as soon as you can today. It's really important that this get taken care of as soon as possible. I'm sorry this sat for so long before being dumped on you. Whatever I can do to help the process along, I will gladly do.

Thanks!

- Bruce

-----Original Message-----

From: (b) (6)
Sent: Tuesday, March 07, 2000 4:31 PM
To: Bruce Ivins (E-mail)
Subject: URL for conference form

<http://www-usamraa.army.mil/>

(b) (6)
(b) (6)
American Society for Microbiology
1752 N Street NW
Washington, DC 20036

(b) (6)

From: Ivins, Bruce E Dr USAMRIID

Sent: Wednesday, March 08, 2000 10:30 AM

To: (b) (6) USAMRIID

Cc: (b) (6) USAMRIID; (b) (6) USAMRIID; (b) (6)

(b) (6)
Subject: PBS

Hi, (b) (6)

(6) Here's the information:

Avant PA and MARP PA was diluted in Avant buffer or Dulbecco's PBS to 0.2 mg/ml. The Absorbance at 280 was read and determined to be 0.2, indicating that the concentrations provided us were correct (Avant PA = 2.5 mg/ml; MARP PA = 1.18 mg/ml). Alhydrogel was added to each tube to an aluminum concentration of 0.5 mg/0.5 ml (the desired concentration of aluminum in a 1/2 ml human dose). The tubes were mixed and allowed to sit overnight at 4C. The Alhydrogel was sedimented by centrifugation, and the supernatant absorbance at 280 nm was read.

Results:

	Avant buffer	Dulbecco's PBS
Avant PA	0.109	0.030
MARP PA	0.110	0.028

These data indicate that adsorption of PA was substantially greater in Dulbecco's PBS (no calcium or magnesium) than in the Avant buffer. This is not surprising, in that there is more twice the phosphate in the Avant buffer, and phosphate is known to interfere with binding to Alhydrogel. The Avant and MARP PA products will be mixed with Alhydrogel and Dulbecco's PBS for the first experiment in rabbits to determine which product, if any, we should choose.

- Bruce

From: Ivins, Bruce E Dr USAMRIID
Sent: Wednesday, March 08, 2000 12:50 PM
To: (b) (6)
Subject: RE: ELISA & TNA

Hi (b) (6)

Good to hear from you again. If we keep this correspondence going I must put you on my list of people to send "jokes" that I receive over email!

For (b) (6) email address, try either of the following:

(b) (6)

or

(b) (6)

I am accustomed to looking just at titers as well. However, it was thought by (b) (6) and others, that determining actual concentrations of anti-PA IgG would be more quantitative (therefore, I guess, more accurate and meaningful). There is a tendency by some around here to be rather anal-retentive about scientific experiments. We still do just titers for animals in routine experiments, but for stuff that's going to the FDA, exact concentrations of specific IgG will be determined.

Let me know if you'd like to be sent some of my "Yankee" humor.

- Bruce

-----Original Message-----

From: (b) (6)
Sent: Wednesday, March 08, 2000 12:05 PM
To: 'Bruce.Ivins'(b) (6)
Subject: ELISA & TNA
Importance: High

Dear Bruce,

Good to have you at the other end of the email line.

One last question on that subject - do you know (b) (6) email address?

Change of subject - thanks for your help with that last one.

I send you the extract below in confidence. It is the response from the resident immunologist/serologist to what is needed in order to do the serology and TNA properly for the planned vaccine and primate trials. It through me into confusion! Firstly, I only became aware of this new view that one should be measuring ug/ml of anti-PA IgG rather than titer as I was reading on the plane coming over! But trying to get an explanation from (b) (6) (b) (6) - he was down here for some of the FDA planning meetings a month ago) of how this is done left me wondering in what way it was more precise than titers for measuring antibody response. And this standard serum thing below.

Is he going over the top a bit? I said we had used a running control for our tests, which was serum from a vaccinated individual. If we were running out of that, we ran it in parallel with another vaccinee serum which then became a control. I said we were more interested in changes with time than absolute values. He certainly makes me feel I have been very amateur in my approach to ELISA over these many years. How do you react to this?

> -----Original Message-----

> From: (b) (6)

>

> For the last several days I have been talking to the folks at USAMRIID
> and my staff trying to develop a laboratory plan for testing specimens
> for the human and animal studies.

>

> There is no standard reference serum for doing ELISA or TNA. This is
> amazing to me considering all the work and years of experience that
> has gone into evaluating this vaccine using serologic techniques.
> What would have to be done is have people get vaccinated (standard
> regimen, 0,2,4, 6 months, maybe 12 months) and then plasmaphorese
> them. After screening the plasma (we have always converted to serum
> at this step), pool, purify out the IgG fraction and then affinity
> purify anti-PA IgG. At this point the mass of the anti-PA would have
> to be determined to assign a ug/ml value for the reference. Next an
> independent measure of antibody done by ELISA would have to be run and
> the mass estimate and ELISA estimate would have to be is reasonable
> agreement. After the anti-PA values are assigned the serum needs to
> be lyophilized in small aliquotes and stored for use and distribution.

>

> The USAMRIID folks estimated that we plasmaphorese 20 people at about
> 500 ml per person and hopefully be able to get about 10 liters of
> starting material to purify.

>

From: Ivins, Bruce E Dr USAMRIID
Sent: Thursday, March 09, 2000 11:32 AM
To: (b) (6) USAMRIID
Subject: FW: Pregnancy and working in anthrax lab

-----Original Message-----

From: (b) (6) USAMRIID
Sent: Thursday, March 09, 2000 7:48 AM
To: (b) (6)
Cc: Ivins, Bruce E Dr USAMRIID; (b) (6)
Subject: RE: Pregnancy and working in anthrax lab

Hi (b) (6)

Regarding the situation of allowing pregnant women to work in a containment laboratory, I submit the following information. During December 1992, I received legal advice from our lawyer representative regarding Pregnant Women in Biocontainment Suites. A few salient comments were:

a. The condition of pregnancy does not appear to in any manner prevent a women from performing operations in a BSL-3 and BSL-3a environment.

b. I can conceive of no risks to other USAMRIID personnel or to anyone else that will be present if a pregnant woman works in such a BSL suite. Consequently, no bona fide occupational qualification exists to lawfully prevent pregnant women from working

in a BSL-3 or BSL-3a suite.

Consequently, it was necessary to identify USAMRIID's responsibilities with regard to pregnant women, their unborn fetuses, and other laboratory employees. (b) (6) and I discussed this issue in August 1993. It was decided to complete a CONSULTATION SHEET (Standard Form 513) for PREGNANCY AND BIOCONTAINMENT. The CONSULTATION REPORT should include the following:

1. Discuss all apparent and potential risks for the biocontainment suite or laboratory (such as immunizations and laboratory-acquired infections).
2. Explain how USAMRIID has identified the risks (such as the type of procedure [aerosol or animal inoculation], and infection or intoxication incidence).
3. Explain that a decision to limit work in a biocontainment suite or laboratory at a particular stage of pregnancy is justified to insure an effective emergency response, if needed.
4. Acknowledge (by signature or initialing) that the individual has understood this consult and was notified of all apparent and potential risks.

From: Ivins, Bruce E Dr USAMRIID
Sent: Thursday, March 09, 2000 11:55 AM
To: (b) (6)
Subject: RE: URL for conference form

(b) (6)
(6) Did (b) (6) get back to you yesterday? I sent him an urgent message on what we talked about over the phone. If he didn't please let me know so I can talk to him and really push this from our end. Sorry for all the hassle we've caused you.

- Bruce

-----Original Message-----

From: (b) (6)
Sent: Tuesday, March 07, 2000 4:31 PM
To: Bruce Ivins (E-mail)
Subject: URL for conference form

<http://www-usamraa.army.mil/>

(b) (6)
American Society for Microbiology
1752 N Street NW
Washington, DC 20036

(b) (6)
(b) (6)

From: Ivins, Bruce E Dr USAMRIID
Sent: Friday, March 10, 2000 10:26 AM
To: (b) (6) USAMRIID
Subject: More notebooks

Hi, (b) (6)

We have more notebooks for you. Please either email me or call me at (b) (6) to let me know when we can bring them down. Thanks!

- Bruce

From: Ivins, Bruce E Dr USAMRIID
Sent: Saturday, March 11, 2000 7:14 PM
To: (b) (6)
Subject: RE: Reprint

(b) (6)

I'll forward this to (b) (6) and have him send you a copy. Unfortunately, the editors never made all of the corrections that we asked them to make.

- Bruce

-----Original Message-----

From: (b) (6)
Sent: Saturday, March 11, 2000 3:52 PM
To: 'Ivins, Bruce E Dr USAMRIID'
Subject: RE: Reprint

Guess who, again, Bruce. Disturbing you in your slumbers and stirring you into action again.

I can now confess I received a manuscript of yours and (b) (6) in (b) (6). I see I didn't want to make it too easy for you and suggested a number of changes (!) - but I did say it was "an extremely well-researched and fully comprehensive review ... readable .. will be well received and widely read"!

Anyhow, I never saw the finished product. Might I have a reprint (or copy) of it please?

Address: (b) (6)

Thanks. When you have executed that command, you can go back to sleep in your arm chair there!

(b)
(6)

From: Ivins, Bruce E Dr USAMRIID
Sent: Monday, March 13, 2000 10:43 AM
To: (b) (6) USAMRIID
Subject: B97-03 necropsies

(b) (6)

Here is what we have for the next several weeks as far as guinea pig necropsies on the B97-03 protocol:

21-24 March (Challenged on 20 March)

11-14 April (Challenged on 10 April)

25-28 April (Challenged on 24 April)

Each strain will have 4 males and 4 females challenged. I don't know how many you want to do of each strain.

- Bruce I.

From: Ivins, Bruce E Dr USAMRIID
Sent: Monday, March 13, 2000 2:10 PM
To: (b) (6)
Subject: FW: Immunoprotective Effects of CpG Oligonucleotides Briefing
Attachments: (b) (6) abstract.doc

>-----Original Message-----

>From: (b) (6) USAMRIID
>Sent: Monday, March 13, 2000 12:50 PM
>To: (b) (6) Ivins, Bruce E Dr USAMRIID
>Subject: FW: Immunoprotective Effects of CpG Oligonucleotides Briefing

>
>
>

>-----

>From: (b) (6) USAMRMC
>Sent: Sunday, March 12, 2000 12:52 PM
>To: (b) (6)

(b) (6)

>Cc: (b) (6)

>Subject: RE: Immunoprotective Effects of CpG Oligonucleotides Briefing

>
>Just another reminder about (b) (6) talk on 20 March. I have attached an abstract of his work. Everyone is welcome to attend.

>
>Thanks,
(b) (6)

>
>
>

>-----Original Message-----

>From: (b) (6) USAMRMC
>Sent: Tuesday, February 22, 2000 10:17 AM
>To: (b) (6)

(b) (6)

(b) (6)

>Cc: (b) (6)

>Subject: Immunoprotective Effects of CpG Oligonucleotides Briefing

>
(b) (6) from the FDA will be visiting Fort Detrick on (b) (6) to brief on the results of studies he's conducted concerning the use of CpG oligos as anti-bioterrorism agents. His briefing will be held at the Dalrymple conference room at RIID. Please consider this message an invitation for you or anyone in your organization who may be interested in attending.

>
>POC for this briefing is (b) (6)

>
>
>Thanks,

>
>(b) (6)

>
>